These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 12668574

  • 21. The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors.
    von Hentig N, Babacan E, Lennemann T, Knecht G, Carlebach A, Harder S, Staszewski S, Haberl A.
    J Antimicrob Chemother; 2008 Sep; 62(3):579-82. PubMed ID: 18477709
    [Abstract] [Full Text] [Related]

  • 22. Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1.
    Murphy RL, Sommadossi JP, Lamson M, Hall DB, Myers M, Dusek A.
    J Infect Dis; 1999 May; 179(5):1116-23. PubMed ID: 10191212
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Amprenavir and ritonavir plasma concentrations in HIV-infected patients treated with fosamprenavir/ritonavir with various degrees of liver impairment.
    Seminari E, De Bona A, Gentilini G, Galli L, Schira G, Gianotti N, Uberti-Foppa C, Soldarini A, Dorigatti F, Lazzarin A, Castagna A.
    J Antimicrob Chemother; 2007 Oct; 60(4):831-6. PubMed ID: 17684056
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks.
    Kosalaraksa P, Bunupuradah T, Engchanil C, Boonrak P, Intasan J, Lumbiganon P, Burger D, Ruxrungtham K, Schutz M, Ananworanich J, HIV-NAT 017 Study Team.
    Pediatr Infect Dis J; 2008 Jul; 27(7):623-8. PubMed ID: 18520443
    [Abstract] [Full Text] [Related]

  • 30. Effect of high-dose vitamin C on the steady-state pharmacokinetics of the protease inhibitor indinavir in healthy volunteers.
    Slain D, Amsden JR, Khakoo RA, Fisher MA, Lalka D, Hobbs GR.
    Pharmacotherapy; 2005 Feb; 25(2):165-70. PubMed ID: 15767232
    [Abstract] [Full Text] [Related]

  • 31. Pharmacokinetics and short-term efficacy of a double-boosted protease inhibitor regimen in treatment-naive HIV-1-infected adults.
    van der Lugt J, Autar RS, Ubolyam S, Garcia EF, Sankote J, Avihingsanon A, Chuenyam T, Cooper DA, Lange J, Phanuphak P, Wit F, Ruxrungtham K, Burger D, HIV-NAT 019 Study Team.
    J Antimicrob Chemother; 2008 May; 61(5):1145-53. PubMed ID: 18285316
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. The use of pharmacokinetically guided indinavir dose reductions in the management of indinavir-associated renal toxicity.
    Boyd MA, Siangphoe U, Ruxrungtham K, Reiss P, Mahanontharit A, Lange JM, Phanuphak P, Cooper DA, Burger DM.
    J Antimicrob Chemother; 2006 Jun; 57(6):1161-7. PubMed ID: 16595641
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Plasma concentrations of the HIV-protease inhibitor lopinavir are suboptimal in children aged 2 years and below.
    Verweel G, Burger DM, Sheehan NL, Bergshoeff AS, Warris A, van der Knaap LC, Driessen G, de Groot R, Hartwig NG.
    Antivir Ther; 2007 Jun; 12(4):453-8. PubMed ID: 17668553
    [Abstract] [Full Text] [Related]

  • 37. A pharmacokinetic drug-drug interaction study of venlafaxine and indinavir.
    Levin GM, Nelson LA, DeVane CL, Preston SL, Eisele G, Carson SW.
    Psychopharmacol Bull; 2001 Jun; 35(2):62-71. PubMed ID: 12397887
    [Abstract] [Full Text] [Related]

  • 38. Pharmacokinetic study of the variability of indinavir drug levels when boosted with ritonavir in HIV-infected children.
    Curras V, Hocht C, Mangano A, Niselman V, Mariño Hernández E, Cáceres Guido P, Mecikovsky D, Bellusci C, Bologna R, Sen L, Rubio MC, Bramuglia GF.
    Pharmacology; 2009 Jun; 83(1):59-66. PubMed ID: 19052483
    [Abstract] [Full Text] [Related]

  • 39. Pharmacokinetics of two randomized trials evaluating the safety and efficacy of indinavir, saquinavir and lopinavir in combination with low-dose ritonavir: the MaxCmin1 and 2 trials.
    Justesen US, Fox Z, Pedersen C, Cahn P, Gerstoft J, Clumeck N, Losso M, Peters B, Obel N, Castagna A, Dragsted UB, Lundgren JD, MaxCmin1 and 2 trial groups.
    Basic Clin Pharmacol Toxicol; 2007 Nov; 101(5):339-44. PubMed ID: 17910618
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.